New Jersey Company Recalls 87 Lots of Losartan for Cancer Risk

Losartan Recall

The recalled 25 mg, 50 mg and 100 mg losartan tablets were found to contain trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), according to an FDA recall notice issued Thursday. Affected products were packaged in 30 count, 90 count, 500 count and 1000 count bottles. A full list of the recalled drugs can be found on the FDA recall page.

It’s the second losartan recall in a week; Macleods Pharmaceuticals Limited recalled a single lot of the medication on Feb. 22.

The recalled medicine was distributed across the U.S. to retail establishments, mail-order pharmacies, wholesalers and distributors.

If you are currently taking the recalled losartan, FDA advises you not to stop until you consult your physician about alternative medications, as doing so could have dire health consequences.

To date, no injuries or other adverse events have been associated with the recalled Losartan, Camber said.

Source: USA TODAY